Chapters

Transcript

Video

Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials

Name: Post-Radical Prostatectomy (RP) Outcome for Patients with High-Risk Prostate Cancer Treated with Intense Neoadjuvant Hormone Therapy (NHT): Results of a Pooled Analysis of Contemporary Clinical Trials
Uploaded: 2021-02-19T00:00:00+00:00
Description: Prostate cancer research: Mary-Ellen Taplin, MD details prostate cancer research findings that indicate decreased PSA relapse rate for patients with a favorable pathologic response to neoadjuvant hormone therapy prior to radical prostatectomy.

Prostate cancer research: Mary-Ellen Taplin, MD details prostate cancer research findings that indicate decreased PSA relapse rate for patients with a favorable pathologic response to neoadjuvant hormone therapy prior to radical prostatectomy.

Published

February 19, 2021

Created by

Related Presenters

Mary-Ellen Taplin, MD

Medical Oncology

Dr. Taplin received her MD in 1986 from the University of Massachusetts, Worcester. She completed a residency in internal medicine and chief residency at the University of Massachusetts Medical Center...

View Profile

Related Videos

Video

ASCO 2023: Bladder Cancer Highlights Presented By Charlene Mantia, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Prostate Cancer Highlights Presented By Jacob Berchuck, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Kidney Cancer Highlights Presented By Vincent (Wenxin) Chu, MD

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ASCO 2023.

Video

ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD

Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.

Video

ASCO 2023: Head And Neck Research Presented by Glenn Hanna, MD

Encouraging anti-tumor activity for patients with metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGF-beta inhibitor BCA101 w/pembrolizumab.

Video

ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD

Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.

Video

ASCO 2023: Prostate Cancer Research Presented by Praful Ravi, MB BCHIR, MRCP

ICECAP collaboration was the largest study looking at the prognostic value of PSA nadir in localized prostate cancer, finding a PSA level of less than 0.1 could provide an early prognosis signal.

Video

ASCO 2023: Treating NUT Carcinoma Research Presented by Jia Luo, MD

Dana-Farber's Jia Luo, MD, details on findings from the NUT Carcinoma Registry on initial chemotherapy for locally advanced and metastatic disease.

Video

ASCO 2023: Kidney Cancer Research Presented by Toni Choueiri, MD

We learn from negative study results as well as from positive ones. Phase 3 study by Dana-Farber's Toni Choueiri, MD, shows that rechallenge with PD-L1 inhibitors in second-line therapy for advanced kidney cancer has no benefit.